ENDONOVO THERAPEUTICS, INC. Net Income (Loss) Attributable to Parent, Diluted
ENDONOVO THERAPEUTICS, INC. (ENDV) reported Net Income (Loss) Attributable to Parent, Diluted of -$480.28 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-12-29.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2023-12-29
- ENDONOVO THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2023-09-30 was -$480.28K.
- ENDONOVO THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2023-06-30 was -$1.04M.
- ENDONOVO THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2023-03-31 was -$496.76K.
- ENDONOVO THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2022-09-30 was -$603.36K.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month |
|---|---|---|---|
| 2023-09-30 | -$480.28K 10-Q · filed 2023-12-29 | -$1.52M derived: sum of 2 quarters · filed 2023-12-29 | -$2.30M 10-Q · filed 2023-12-29 |
| 2023-06-30 | -$1.04M 10-Q · filed 2023-08-21 | -$1.53M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | -$496.76K 10-Q · filed 2023-05-22 | ||
| 2022-09-30 | -$603.36K 10-Q · filed 2023-12-29 | -$3.13M derived: sum of 2 quarters · filed 2023-12-29 | -$5.54M 10-Q · filed 2023-12-29 |
| 2022-06-30 | -$2.53M 10-Q · filed 2023-08-21 | -$4.94M 10-Q · filed 2023-08-21 | |
| 2022-03-31 | -$10.24M 10-Q · filed 2023-05-22 |